PMID- 34339705
OWN - NLM
STAT- MEDLINE
DCOM- 20211222
LR  - 20211222
IS  - 1096-0945 (Electronic)
IS  - 0014-4800 (Linking)
VI  - 122
DP  - 2021 Oct
TI  - Prognostic and clinicopathological significance of TMEFF2, SMOC-2, and SOX17 
      expression in endometrial carcinoma.
PG  - 104670
LID - S0014-4800(21)00069-1 [pii]
LID - 10.1016/j.yexmp.2021.104670 [doi]
AB  - Background there is a need for novel biomarkers and targeting therapies for 
      predicting Endometrial carcinoma (EC) progression and recurrence. TMEFF2 is a 
      gene that was found to play a role in EMT. SMOC-2 is expressed in embryogenesis 
      and it was identified as a recent stem cell-related gene that has a role in 
      cancer progression. SRY-box 17 (SOX17) is a member of the SRY-related HMG-box 
      (SOX) family of transcription factors. Dysregulation or downregulation of SOX17 
      expression was found in many cancer tissues. AIM: In the present study, we aimed 
      to assess the tissue protein expressions of TMEFF2, SMOC-2, and SOX17 in EC using 
      immunohistochemistry to evaluate their clinicopathological values and prognostic 
      roles in EC patients. PATIENTS AND METHODS: This is prospective cohort study 
      included 120 patients with EC. Sections from 120 paraffin blocks were retrieved 
      and stained with TMEFF2, SMOC-2, and SOX17 using immunohistochemistry, the 
      expression of markers in all tissue samples was assessed, analyzed and 
      correlation of pathological parameters with the levels of expression was done. 
      All patients were followed up till death or till the last known alive data for 
      about 50 months (range from 25 to 60). RESULTS: TMEFF2, SMOC-2 expression was 
      correlated with the presence of lymph node metastases (p = 0.023), distant 
      metastasis (p = 0.039) recurrence of the tumor after successful therapy, overall 
      survival, and disease-free survival (p < 0.001). SOX17 positive expression was 
      positively correlated with low grade (p = 0.019), absence of lymph node 
      metastasis (p = 0.001), absence of distant metastasis (p = 0.013), low stage 
      (p = 0.03), and its negative expression was positively correlated with recurrence 
      of the tumor after successful therapy, overall survival and disease-free survival 
      (p = 0.001). In conclusion, we demonstrated that both TMEFF2 and SMOC-2 were 
      highly expressed in EC and were associated with a shortened survival rate, dismal 
      outcome, and poor prognosis in EC patients. While SOX17 expression was related to 
      a favorable outcome and its down-regulation was associated with dismal EC 
      patient's survival.
CI  - Copyright (c) 2021 Elsevier Inc. All rights reserved.
FAU - Alabiad, Mohamed Ali
AU  - Alabiad MA
AD  - Department of Pathology, Faculty of Medicine, Zagazig University, Zagazig, Egypt. 
      Electronic address: maabyad@medicine.zu.edu.eg.
FAU - Harb, Ola A
AU  - Harb OA
AD  - Department of Pathology, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
FAU - Hefzi, Nabila
AU  - Hefzi N
AD  - Department of Clinical Oncology& Nuclear Medicine, Faculty of Medicine, Zagazig 
      University, Zagazig, Egypt.
FAU - Ahmed, Rham Z
AU  - Ahmed RZ
AD  - Department of Medical Oncology, Faculty of Medicine, Zagazig University, Zagazig, 
      Egypt.
FAU - Osman, Gamal
AU  - Osman G
AD  - Department of General Surgery, Faculty of Medicine, Zagazig University, Zagazig, 
      Egypt.
FAU - Shalaby, Amany Mohamed
AU  - Shalaby AM
AD  - Department of Histology and Cell Biology, Faculty of Medicine, Tanta University, 
      Tanta, Egypt.
FAU - Alnemr, Amr Abd-Almohsen
AU  - Alnemr AA
AD  - Department of Gynecology and Obstetrics, Faculty of Medicine, Zagazig University, 
      Zagazig, Egypt.
FAU - Saraya, Yasser S
AU  - Saraya YS
AD  - Department of Gynecology and Obstetrics, Faculty of Medicine, Zagazig University, 
      Zagazig, Egypt.
LA  - eng
PT  - Journal Article
DEP - 20210731
PL  - Netherlands
TA  - Exp Mol Pathol
JT  - Experimental and molecular pathology
JID - 0370711
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Calcium-Binding Proteins)
RN  - 0 (Membrane Proteins)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (SMOC2 protein, human)
RN  - 0 (SOX17 protein, human)
RN  - 0 (SOXF Transcription Factors)
RN  - 0 (TMEFF2 protein, human)
SB  - IM
MH  - Adult
MH  - Biomarkers, Tumor/genetics
MH  - Calcium-Binding Proteins/*genetics
MH  - Cell Line, Tumor
MH  - Cell Proliferation/genetics
MH  - Disease-Free Survival
MH  - Endometrial Neoplasms/*genetics/pathology
MH  - Female
MH  - Gene Expression Regulation, Neoplastic/genetics
MH  - Humans
MH  - Lymphatic Metastasis/genetics/pathology
MH  - Membrane Proteins/*genetics
MH  - Middle Aged
MH  - Neoplasm Proteins/*genetics
MH  - Prognosis
MH  - SOXF Transcription Factors/*genetics
OTO - NOTNLM
OT  - Endometrial carcinoma
OT  - Immunohistochemistry
OT  - Prognosis
OT  - SMOC-2
OT  - SOX17
OT  - TMEFF2
EDAT- 2021/08/03 06:00
MHDA- 2021/12/24 06:00
CRDT- 2021/08/02 20:12
PHST- 2020/12/27 00:00 [received]
PHST- 2021/06/21 00:00 [revised]
PHST- 2021/07/29 00:00 [accepted]
PHST- 2021/08/03 06:00 [pubmed]
PHST- 2021/12/24 06:00 [medline]
PHST- 2021/08/02 20:12 [entrez]
AID - S0014-4800(21)00069-1 [pii]
AID - 10.1016/j.yexmp.2021.104670 [doi]
PST - ppublish
SO  - Exp Mol Pathol. 2021 Oct;122:104670. doi: 10.1016/j.yexmp.2021.104670. Epub 2021 
      Jul 31.